UCB announces rozanolixizumab BLA for the treatment of gener

Biologic License Application (BLA) designated Priority Review by FDA and seeks approval for rozanolixizumab for the treatment of adults with generalized...

Related Keywords

Brussels , Bruxelles Capitale , Belgium , China , Denmark , Daphne Teo , Charl Van Zyl , Jim Baxter , Iris Loew Friedrich , Antje Witte , Laurent Schots , Us Communications , Brand Communications , Eu International , Twitter , European Commission , Drug Administration , Neurology Solutions Head , Corporate Communications , Myasthenia Gravis Foundation Of America , European Medicines Agency , Lancet Reg Health West Pac , Committee For Medicinal Products Human Use , Drug Administration Accessed , Biologic License Application , Priority Review , Marketing Authorization Application , Medicinal Products , Human Use , Executive Vice President Neurology Solutions , International Markets , Executive Vice President , Chief Medical Officer , Review Designation , Generalized Myasthenia Gravis , Myasthenia Gravis Activities , Daily Living , Myasthenia Gravis , Rare Diseases , Euronext Brussels , Accessed January , Medicines Agency , Gravis Foundation , Clinical Overview , Patients With Moderate , Severe Generalized Myasthenia Gravis , Multicenter Clinical , Reg Health West Pac , Neurological Disorders , Gravis Fact , Life Outcomes , Test Efficacy , Ucb ,